Member Info for martinu

FS, it's not a summary it lists all questions and answers and is too long to cut and paste. You will get the same info if you go to the website. Though you do have to go through the menu to find Q&A.

I couldn't submit questions on phone as the submit tab dropped out of sight. But no problems using laptop. Good luck.

in the recent trading update pbx said that q126 order book was £1.3m. a similar comment for q125 was £620k.

with annual revenue for fy25 turning out to be £2.7m that averages out at £675k per qtr. if the stated order book for q126 of £1.3m translates into booked sales (as it did last year; it was actually exceeded), then the tw (*************) f/c of revenue for fy26 of £4m could be quite conservative but actually sensible. pbx might be nearer to £5m revs this year. now that's me getting excited.

Oh dear! No more Director Buys please! :)

Thanks for sharing shychap. At least they confirmed they are working on getting out the HY figures "in the coming weeks ". Which of course is open to interpretation. But a chance, if it happens, of a couple of ticks in the positive box. One, if they are prompt; two, if they show good growth in revenues.

Great to see another Director buy today. £12k's worth.

Agree. I've asked and had responses to a few questions. A great initiative which might give prospective shareholders a bit of confidence.

Thanks Toyin. Interestingly there is an acne product mentioned at the top of the article. Our Axisbiotix seems to offer better efficacy than that.

I wonder what Mark Dixon's views on further acquisitions are? (I'm not keen.) Or would he not be interested in such issues?

Veritas, absolutely agree re PBX. I think Steen's aspiration of £10m sales might take a while, but I'm very happy with progress there.

On SBTX, I agree they could appreciate this year, but is there some nervousness over Croda customers' delay in launching a Zenakine product.

As for Opti, things are looking more positive there. But consistently growing numbers will be needed to restore market confidence.

Around 10 months ago now.

Jan was for IMC see results RNS. Feb was an aspiration for TU (given in an interview I think).

Half year report was March last year but said they would try to get trading update out earlier this year. End of Feb hoped for but not promised as I recall.

No point in IMC if nothing to say. Don't need a "this is what we do" IMC. Silly to mention it at all.

Also, if any of you haven't signed up for new Q&A facility on website, I strongly recommend you do.

This Q&A from / to Andy777 is particularly positive on Amazon, China (after change to partner) and for Asia in FY26

Andy777

"Hi. Have the ecommerce sales continued to grow significantly into H2 2025 and early 2026. How important is the ecommerce relative to deals with companies like Morepen, and the other US and asian companies?

Hi, Ecommerce is one of four areas we have been investing in to grow. These are Asia, India, USA and what we call Consumer Health (Amazon, our own website, Ebay, China and recently India). Amazon is one of the worlds biggest ecommerce market place which we have invested in to build a large customer base and it continued to grow in 2025 with marketing investment. Our focus now is on profitability on Amazon which we hope to achieve this month or next. This should then grow into a highly profitable business. Our own website is already profitable. China should become profitable in Q2 as we changed our partner last summer and have been clearing stock with a short shelf life at discount. Once this is clear we should be profitable in China. This is all part of building a business - building a brand, product range and customer base. Ecommerce is part of that mix and reduces our dependency on partners. You cannot have a dependency on one part of the business, one product, one partner, or one country. We need more partners in India and the USA to reduce any future dependency. Asia is showing great growth and will make a significant contribution to sales in 2026. "

Good posts both mol and ox. Thanks for helpful info.

It would be nice if we could beat last year's high of 12/13p

I would guess (and that's the point we shouldn't have to), that the Nov 25 order (included in the £800k total) will be booked in 2026. This is an opportunity to seek clarity via the new Q&A portal. Responses are coming within a day.

From interims to Jun 25 published September. Extra cost.

" Appointment of new sales executive in the US expected to drive further growth in North America"

Plus possibly costs associated with two new upcoming studies?

Wigster, that is a good point. Costs have risen more than I expected too. Possibly some due to move to new segment of Aquis/ adviser. Also (see extract below) from RNS.

"Alongside the commercial momentum, we implemented a number of internal initiatives to enhance operational scalability, and improve the path to profitability."

ST costs for LT gain maybe?

Yes positive update. Good that clarification was given that these orders will be recorded as revenues in FY 26. As sometimes Opti orders take months to be recognised. Fingers crossed for more progress.

Yes, agree. A strong and prompt update. This share must get on to more people's radar soon. Main figures:

· Sales +45% to £2.72m (2024: £1.88m)

· Gross profit +46% to £1.46m (2024: £997,000)

· EBITDA loss from continuing operations down 31% to £445,000 (2024: £642,000)**

· Gross Profit margin increased to 54% (2024: 53%)

· Strong cash balance of £1.27m at year-end

· Record Q1 2026 order book +110% at £1.3m